Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1977 1
1980 1
1981 1
1982 1
1983 1
1984 4
1985 1
1986 1
1987 2
1988 2
1989 2
1990 1
1991 2
1992 1
1993 1
1994 2
1995 2
1996 4
1997 4
1998 16
1999 7
2000 7
2001 7
2002 2
2003 11
2004 9
2005 16
2006 14
2007 6
2008 13
2009 11
2010 12
2011 10
2012 19
2013 12
2014 16
2015 19
2016 23
2017 16
2018 22
2019 40
2020 33
2021 39
2022 34
2023 11
Text availability
Article attribute
Article type
Publication date

Search Results

414 results
Results by year
Filters applied: . Clear all
Page 1
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. Among authors: mizuno r. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Editorial Comment.
Kikuchi E, Mizuno R. Kikuchi E, et al. Among authors: mizuno r. J Urol. 2020 Jun;203(6):1084. doi: 10.1097/JU.0000000000000523.01. Epub 2020 Mar 5. J Urol. 2020. PMID: 32134339 No abstract available.
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Tamada S, Kondoh C, Matsubara N, Mizuno R, Kimura G, Anai S, Tomita Y, Oyama M, Masumori N, Kojima T, Matsumoto H, Chen M, Li M, Matsuda K, Tanaka Y, Rini BI, Uemura H. Tamada S, et al. Among authors: mizuno r. Int J Clin Oncol. 2022 Jan;27(1):154-164. doi: 10.1007/s10147-021-02014-7. Epub 2021 Nov 20. Int J Clin Oncol. 2022. PMID: 34800178 Free PMC article. Clinical Trial.
Editorial Comment.
Kikuchi E, Mizuno R. Kikuchi E, et al. Among authors: mizuno r. J Urol. 2019 Jun;201(6):1104. doi: 10.1097/01.JU.0000554682.07201.49. J Urol. 2019. PMID: 30920342 No abstract available.
Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy.
Takamatsu K, Tanaka N, Hakozaki K, Takahashi R, Teranishi Y, Murakami T, Kufukihara R, Niwa N, Mikami S, Shinojima T, Sasaki T, Sato Y, Kume H, Ogawa S, Kakimi K, Kamatani T, Miya F, Tsunoda T, Aimono E, Nishihara H, Sawada K, Imamura T, Mizuno R, Oya M. Takamatsu K, et al. Among authors: mizuno r. Nat Commun. 2021 Sep 20;12(1):5547. doi: 10.1038/s41467-021-25865-0. Nat Commun. 2021. PMID: 34545095 Free PMC article.
Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
Masuda T, Tanaka N, Takamatsu K, Hakozaki K, Takahashi R, Anno T, Kufukihara R, Shojo K, Mikami S, Shinojima T, Kakimi K, Tsunoda T, Aimono E, Nishihara H, Mizuno R, Oya M. Masuda T, et al. Among authors: mizuno r. J Immunother Cancer. 2022 Mar;10(3):e003883. doi: 10.1136/jitc-2021-003883. J Immunother Cancer. 2022. PMID: 35314433 Free PMC article.
414 results